Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.

Portfolio

Loading...
Select Portfolio and Asset Combination for Display on Market Band
Select Portfolio
Select Asset Class
Show More
Download ET MARKETS APP

Get ET Markets in your own language

DOWNLOAD THE APP NOW

+91

CHOOSE LANGUAGE

ENG

  • ENG - English
  • HIN - हिन्दी
  • GUJ - ગુજરાતી
  • MAR - मराठी
  • BEN - বাংলা
  • KAN - ಕನ್ನಡ
  • ORI - ଓଡିଆ
  • TEL - తెలుగు
  • TAM - தமிழ்
Drag according to your convenience
ET NOW RADIO
ET NOW
TIMES NOW

Corrected: Cycling - Froome says asthma drug behind 'adverse finding'

Reuters|
Dec 13, 2017, 02.20 PM IST
0Comments

(Corrects blood to urine in second para)

(Reuters) - Four-time Tour de France winner Chris Froome said on Wednesday he followed medical advice by taking an increased dosage of asthma medication at the Vuelta a Espana in September.

Cycling's world governing body (UCI) has notified the Briton of an 'Adverse Analytical Finding" from a urine sample taken after Stage 18 of the race. The sample had double the permissible limit of Salbutamol, which is permitted as a legal asthma drug by the Word Anti-Doping Agency.

"It is well known that I have asthma and I know exactly what the rules are," the Team Sky rider, who won the Vuelta, said in a statement.

"I use an inhaler to manage my symptoms (always within the permissible limits) and I know for sure that I will be tested every day I wear the race leader's jersey.

"My asthma got worse at the Vuelta so I followed the team doctor's advice to increase my Salbutamol dosage. As always, I took the greatest care to ensure that I did not use more than the permissible dose."

The UCI said in a statement: "The analysis of the B sample has confirmed the results of the rider's A sample and the proceedings are being conducted in line with the UCI Anti-Doping Rules".

(Reporting by Sudipto Ganguly in Mumbai; editing by Peter Rutherford)

(This story has not been edited by economictimes.com and is auto–generated from a syndicated feed we subscribe to.)
0Comments
Comments
Add Your Comments

Loading
Please wait...